Immunoassay Developed for Legionnaires' Disease
|
By LabMedica International staff writers Posted on 29 Sep 2011 |
|
Separate measurement of antibodies to Legionella pneumophila serogroups as single antigens can facilitate an early diagnosis of Legionnaires' disease.
An enzyme-linked immunosorbent assay (ELISA) was developed and evaluated to determine whether separate measurement of immunoglobulin (Ig) M and G antibodies to L. pneumophila serogroups 1, 3 and 6 as single antigens can assist in the diagnosis.
Scientists at the Statens Serum Institut (Copenhagen, Denmark) compared the ELISA with an in-house indirect Legionella immunofluorescence antibody test (IFAT) measuring Total Ig. A total of 193 sera from 128 patients with confirmed L. pneumophila infections were used to assess the sensitivity of the developed ELISA. The sensitivity was assessed in different time-periods after onset of symptoms. L. pneumoniae infection was confirmed by one or more of the following methods: culture by standard method, Legionella urinary antigen EIA (Biotest AG, Dreieich, Germany), and an in-house polymerase chain reaction (PCR) method.
It was found that the sensitivity of the ELISA increased during the first month of infection, IgM being the most sensitive; ranging from 13% in the first week after onset of symptoms, 45% in the second week to 84% in the third week; in the fourth week and beyond, a drop to 67% was discerned. The IFAT detecting L. pneumophila subgroups 1–6 had a sensitivity of 11%, 27%, 80%, and 59%, respectively, during these time-periods. The test with the lowest sensitivity during these time-periods was the IgG ELISA (0%, 21%, 36%, and 52%) respectively, but by combining the IgG results with the IgM results, the overall sensitivity of the assay was improved (13%, 48%, 88%, and 70%), respectively.
The in-house methods IgM ELISA and IFAT both had a low false positive rate: 7% and 4% among 75 samples. In contrast, the IgG ELISA had a false positive rate of 14%, which was high compared to the other tests. The sera which were positive for Helicobacter pylori, Salmonella typhimurium/enteritidis, and Mycoplasma pneumoniae showed the highest rate of false positive in the IgG subgroup1 ELISA. The sera, which caused the false positive results in the IFAT and IgM ELISA were the sera with antibodies to Proteus species and S. typhimurium/enteritidis.
The study confirmed that detection of IgG and IgM antibodies by ELISA is an important diagnostic tool especially during the initial phase of the disease, when supported by other tests like the urinary antigen test, PCR, or culture of the organism. The authors concluded that specific antibodies against L. pneumophila subgroups 1, 3, and 6 can be detected in patients early in the course of infection. Furthermore, positive IgM level can be used as a good indicator of an ongoing or recent Legionella infection. The study was published in September 2011, in the Journal of Microbiological Methods.
Related Links:
Statens Serum Institut
Biotest AG
An enzyme-linked immunosorbent assay (ELISA) was developed and evaluated to determine whether separate measurement of immunoglobulin (Ig) M and G antibodies to L. pneumophila serogroups 1, 3 and 6 as single antigens can assist in the diagnosis.
Scientists at the Statens Serum Institut (Copenhagen, Denmark) compared the ELISA with an in-house indirect Legionella immunofluorescence antibody test (IFAT) measuring Total Ig. A total of 193 sera from 128 patients with confirmed L. pneumophila infections were used to assess the sensitivity of the developed ELISA. The sensitivity was assessed in different time-periods after onset of symptoms. L. pneumoniae infection was confirmed by one or more of the following methods: culture by standard method, Legionella urinary antigen EIA (Biotest AG, Dreieich, Germany), and an in-house polymerase chain reaction (PCR) method.
It was found that the sensitivity of the ELISA increased during the first month of infection, IgM being the most sensitive; ranging from 13% in the first week after onset of symptoms, 45% in the second week to 84% in the third week; in the fourth week and beyond, a drop to 67% was discerned. The IFAT detecting L. pneumophila subgroups 1–6 had a sensitivity of 11%, 27%, 80%, and 59%, respectively, during these time-periods. The test with the lowest sensitivity during these time-periods was the IgG ELISA (0%, 21%, 36%, and 52%) respectively, but by combining the IgG results with the IgM results, the overall sensitivity of the assay was improved (13%, 48%, 88%, and 70%), respectively.
The in-house methods IgM ELISA and IFAT both had a low false positive rate: 7% and 4% among 75 samples. In contrast, the IgG ELISA had a false positive rate of 14%, which was high compared to the other tests. The sera which were positive for Helicobacter pylori, Salmonella typhimurium/enteritidis, and Mycoplasma pneumoniae showed the highest rate of false positive in the IgG subgroup1 ELISA. The sera, which caused the false positive results in the IFAT and IgM ELISA were the sera with antibodies to Proteus species and S. typhimurium/enteritidis.
The study confirmed that detection of IgG and IgM antibodies by ELISA is an important diagnostic tool especially during the initial phase of the disease, when supported by other tests like the urinary antigen test, PCR, or culture of the organism. The authors concluded that specific antibodies against L. pneumophila subgroups 1, 3, and 6 can be detected in patients early in the course of infection. Furthermore, positive IgM level can be used as a good indicator of an ongoing or recent Legionella infection. The study was published in September 2011, in the Journal of Microbiological Methods.
Related Links:
Statens Serum Institut
Biotest AG
Gold Member
Troponin T QC
Troponin T Quality Control
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
Latest Microbiology News
- Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
- 30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease
- CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening
- Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read more
Molecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Pathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read more
Technology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
